drugset / Trial / NCT07442630

Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides

NCT07442630

Phase 4 Active not recruiting 88 enrolled JW Pharmaceutical
RandomizedParallel-groupTriple-blindTreatment

Summary

A multicenter, randomized, double-blind, phase Ⅳ study to evaluate the long-term efficacy and safety of Pitavastatin/Ezetimibe and Pitavastatin in patients with hypercholesterolemia with elevated triglycerides

Timeline

Start
2023-08-21
Primary completion
2026-01-22
Completion
2026-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown 10 mg Oral
Subject Pitavastatin Small molecule 4 mg Oral

Indications